Latest Breaking News On - Durvalumab imfinzi - Page 3 : vimarsana.com

Durvalumab regimen confers durable survival benefit in unresectable liver cancer

Durvalumab regimen confers durable survival benefit in unresectable liver cancer
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Durvalumab imfinziMindy valcarcelBymatthew shinkleBruno sangroWorld congress on gastrointestinal cancerGastrointestinal cancerUniversidad de navarra

Durvalumab Plus Tremelimumab Elicits Clinically Meaningful, 4-Year OS Advantage in Advanced HCC

Durvalumab plus a single priming dose of tremelimumab led to continued clinically meaningful overall survival benefit at 4 years compared with sorafenib in patients with previously untreated, unresectable hepatocellular carcinoma not eligible for localized therapy.

Bruno sangroDurvalumab imfinziSusan galbraithLiver unitInternal medicineUniversidad de navarra

Durvalumab, Olaparib Combination Improves Progression-Free Survival in Patients With Advanced Ovarian Cancer

Positive findings in patients with advanced high-grade epithelial ovarian cancer were presented during an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting.

Susan galbraithDurvalumab imfinziPhilipp harterEvangelische kliniken essen mitteDepartment of gynecologyGynecologic oncology

AstraZeneca Pharma shares gain 3% on CDSCO approval to sale Tremelimumab in India

The receipt of this permission paves way for the launch of Tremelimumab (Imjudo) solution of 20 mg/ml in India.

Durvalumab imfinziTrastuzumab deruxtecanAstrazeneca pharmaTremelimumab imjudoCentral drugs standard control organisationHealth servicesZeneca pharma indiaDirectorate generalGovernment of indiaFinancial yearAstrazeneca pharma indiaAstrazeneca pharma india share price

Durvalumab regimens extend PFS in advanced endometrial cancer

The addition of durvalumab to chemotherapy — either alone or in combination with olaparib — improved outcomes for women with advanced endometrial cancer, according to the agent’s manufacturer.Chemotherapy is standard first-line treatment for women with advanced endometrial cancer; however, long-term outcomes remain poor and more effective treatment options are needed.

Durvalumab imfinziOlaparib lynparzaMark leiserShannonn westinMd anderson cancer centerCancer center